Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Xspray Pharma AB ( (SE:XSPRAY) ) has provided an announcement.
Xspray Pharma AB has secured additional subscription commitments totaling SEK 20 million from new investors as part of its ongoing rights issue and over-allotment issue. This brings the total coverage of the rights issue to 83%, equivalent to approximately SEK 109 million, enhancing the company’s financial position and supporting its strategic initiatives in the oncology market.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in the development of improved versions of marketed protein kinase inhibitors (PKIs) using its patented HyNap™ technology platform. The company aims to lead the market in enhanced PKIs for cancer treatment, with its lead drug candidate, Dasynoc®, currently under FDA review. Xspray Pharma is also developing other optimized drug versions, including XS003-nilotinib, XS008-axitinib, and XS025-cabozantinib.
YTD Price Performance: 5.00%
Average Trading Volume: 39,069
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.59B
For a thorough assessment of XSPRAY stock, go to TipRanks’ Stock Analysis page.